Erika Matos

3.6k total citations
27 papers, 409 citations indexed

About

Erika Matos is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erika Matos has authored 27 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erika Matos's work include Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (11 papers) and Advanced Breast Cancer Therapies (6 papers). Erika Matos is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (11 papers) and Advanced Breast Cancer Therapies (6 papers). Erika Matos collaborates with scholars based in Slovenia, Switzerland and Serbia. Erika Matos's co-authors include Tanja Ovčariček, Branko Zakotnik, Cvetka Grašič Kuhar, Fernando Pardal, Peter Vuylsteke, Étienne Brain, Nuno Costa, Rok Blagus, Khalil Zaman and Borut Jug and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Erika Matos

24 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erika Matos Slovenia 8 210 199 105 75 57 27 409
Eleni Zografos Greece 13 233 1.1× 160 0.8× 183 1.7× 112 1.5× 32 0.6× 43 497
Xiaojia Wang China 13 339 1.6× 221 1.1× 216 2.1× 163 2.2× 64 1.1× 46 620
Lauren Nye United States 9 270 1.3× 115 0.6× 58 0.6× 76 1.0× 42 0.7× 37 369
Carolyn Cullinane Ireland 10 188 0.9× 163 0.8× 78 0.7× 78 1.0× 83 1.5× 29 366
Monica Milano Italy 10 311 1.5× 176 0.9× 134 1.3× 138 1.8× 42 0.7× 22 489
Olga Oikonomidou United Kingdom 9 149 0.7× 119 0.6× 102 1.0× 66 0.9× 50 0.9× 28 320
Satoe Fujiwara Japan 14 227 1.1× 169 0.8× 279 2.7× 72 1.0× 35 0.6× 38 677
Erion Dobi France 14 217 1.0× 111 0.6× 74 0.7× 147 2.0× 28 0.5× 31 356
Jennifer Kane United States 11 191 0.9× 190 1.0× 152 1.4× 44 0.6× 45 0.8× 26 487

Countries citing papers authored by Erika Matos

Since Specialization
Citations

This map shows the geographic impact of Erika Matos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Matos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Matos more than expected).

Fields of papers citing papers by Erika Matos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Matos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Matos. The network helps show where Erika Matos may publish in the future.

Co-authorship network of co-authors of Erika Matos

This figure shows the co-authorship network connecting the top 25 collaborators of Erika Matos. A scholar is included among the top collaborators of Erika Matos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Matos. Erika Matos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Božović‐Spasojević, Ivana, Ana Cvetanović, Assia Konsoulova, et al.. (2024). Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies. Radiology and Oncology. 58(2). 258–267. 2 indexed citations
2.
Matos, Erika, et al.. (2024). Efficacy and safety of abemaciclib in the treatment of HR+ HER2-advanced breast cancer: real world data. European Journal of Cancer. 200. 113712–113712. 1 indexed citations
3.
4.
Borštnar, Simona, et al.. (2022). Intraoperative Touch Imprint Cytology in Breast Cancer Patients After Neoadjuvant Chemotherapy. Clinical Breast Cancer. 22(4). e597–e603. 3 indexed citations
5.
Matos, Erika & Tanja Ovčariček. (2021). Breast cancer during pregnancy: retrospective institutional case series. Radiology and Oncology. 55(3). 362–368. 4 indexed citations
6.
Godina, Elena, et al.. (2020). 207P 10-year real-world outcomes with neoadjuvant systemic therapy in non-inflammatory breast cancer. Annals of Oncology. 31. S324–S325. 1 indexed citations
7.
Matos, Erika, et al.. (2020). Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting. Cancer Treatment and Research Communications. 25. 100201–100201. 6 indexed citations
8.
Cardoso, Fátima, Laura van ‘t Veer, Coralie Poncet, et al.. (2020). MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.. Journal of Clinical Oncology. 38(15_suppl). 506–506. 41 indexed citations
9.
Ovčariček, Tanja, Iztok Takač, & Erika Matos. (2019). Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer. Radiology and Oncology. 53(3). 285–292. 9 indexed citations
10.
Borštnar, Simona, Ana Blatnik, Andraž Perhavec, et al.. (2019). Smernice diagnostike in zdravljenja raka dojk. SHILAP Revista de lepidopterología. 1 indexed citations
11.
Matos, Erika, Borut Jug, Rok Blagus, & Branko Zakotnik. (2016). A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients. Arquivos Brasileiros de Cardiologia. 107(1). 40–7. 18 indexed citations
12.
13.
Kuhar, Cvetka Grašič & Erika Matos. (2014). Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report. BMC Research Notes. 7(1). 325–325. 5 indexed citations
14.
Gazić, Barbara, et al.. (2014). Prognostic value of routinely determined tumor infiltrating lymphocytes in triple-negative breast cancer.. Journal of Clinical Oncology. 32(15_suppl). 1125–1125. 3 indexed citations
15.
Matos, Erika, Branko Zakotnik, & Cvetka Grašič Kuhar. (2013). Effectiveness of adjuvant trastuzumab in daily clinical practice. Radiology and Oncology. 48(4). 403–407. 7 indexed citations
16.
Matos, Erika. (2012). Treatment of HER2 positive breast cancer patients. SHILAP Revista de lepidopterología. 1 indexed citations
17.
Ovčariček, Tanja, et al.. (2011). Triple negative breast cancer - prognostic factors and survival. Radiology and Oncology. 45(1). 46–52. 178 indexed citations
18.
Matos, Erika, et al.. (2010). Fertility in patients treated for testicular cancer. Journal of Cancer Survivorship. 4(3). 274–278. 29 indexed citations
19.
Matos, Erika & Tanja Čufer. (2007). Adjuvant treatment of breast cancer patients with trastuzumab. Radiology and Oncology. 41(3). 2 indexed citations
20.
Costa, Nuno, et al.. (2004). Secretory breast carcinoma—case report and review of the medical literature. The Breast. 13(4). 353–355. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleni Zografos Breakdown of academic impact, for papers by Xiaojia Wang Breakdown of academic impact, for papers by Lauren Nye Breakdown of academic impact, for papers by Carolyn Cullinane Breakdown of academic impact, for papers by Monica Milano Breakdown of academic impact, for papers by Olga Oikonomidou Breakdown of academic impact, for papers by Satoe Fujiwara Breakdown of academic impact, for papers by Erion Dobi Breakdown of academic impact, for papers by Jennifer Kane
Rankless by CCL
2026